Please use this identifier to cite or link to this item: http://repositorio.unifesp.br/handle/11600/37785
Title: A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Authors: King, Talmadge E.
Bradford, Williamson Z.
Castro-Bernardini, Socorro
Fagan, Elizabeth A.
Glaspole, Ian
Glassberg, Marilyn K.
Gorina, Eduard
Hopkins, Peter M.
Kardatzke, David
Lancaster, Lisa
Lederer, David J.
Nathan, Steven D.
Pereira, Carlos A. [UNIFESP]
Sahn, Steven A.
Sussman, Robert
Swigris, Jeffrey J.
Noble, Paul W.
ASCEND Study Grp
Univ Calif San Francisco
InterMune
Cedars Sinai Med Ctr
Neumocare
Alfred Hosp
Prince Charles Hosp
Univ Miami
Vanderbilt Univ
Columbia Univ
Inova Fairfax Hosp
Universidade Federal de São Paulo (UNIFESP)
Med Univ S Carolina
Atlantic Hlth Syst
Natl Jewish Hlth
Issue Date: 29-May-2014
Publisher: Massachusetts Medical Soc
Citation: New England Journal of Medicine. Waltham: Massachusetts Medical Soc, v. 370, n. 22, p. 2083-2092, 2014.
Abstract: BACKGROUNDIn two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients.METHODSIn this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. the primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis.RESULTSIn the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation.CONCLUSIONSPirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.)
URI: http://repositorio.unifesp.br/handle/11600/37785
ISSN: 0028-4793
Other Identifiers: http://dx.doi.org/10.1056/NEJMoa1402582
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.